pancreatic cancer
Conditions
Interventions
Induction chemotherapy withgemcitabine plus nab-Paclitaxel followed by gemcitabine plus nab-Paclitaxel CRT
Sponsors
Department of Gastroenterological Surgery, Osaka Medical Center for Cancer & Cardiovascular Diseases
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients with resectable pancreatic cancer (JPS-T3/T4) (2) PS(ECOG):0 or 1 (3) Adequate bone marrow reserves, liver/renal function: WBC:>=3500/mm3, <=12000/mm3 Neutrophil:>=1500/m3 Platelet:>=100000/mm3 Hb:>=9.5g/dl GOT, GPT, AL-P:less than 2-fold of the upper limit of normal range TBil:<=1.5mg/dl Cr:<=1.2mg/dl CCr>=50ml/min PaO2:>=70torr (4)Life expectancy more than 6 months. (5) Written informed consent
Exclusion criteria
Exclusion criteria: (1)evident infection (2)Lung fibrosis or intestinal pneumonia, and anamnesis or imaging findings. (3)Severe complication(liver cirrhosis, uncontrolled diabetes etc) (4)the onset of myocardial infarction within 3 months (5)active synchronous malignancy (6) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy (7)history of severe drug allergy (8)neuropathy (9)patients who are judged inappropriate for the entry of the trial by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease free survival, Response (either radiological or pathological), R0 resection rate, safety, pattern of recurrence | — |
Countries
Japan
Contacts
Public ContactHidenori Takahashi
Osaka Medical Center for Cancer and Cardiovascular Diseases Gastroenterological Surgery
Outcome results
None listed